Achieve Life Sciences Inc

Latest Report Overview

Achieve Life Sciences Inc (ACHV) reported For the quarterly period ended March 31, 2026 (Issuer fiscal Q1 FY2026) revenue of $0 million with diluted EPS of $-0.19 and net income of $-10 million. free cash flow was $-7 million for the period. The company’s operational focus remains on its clinical development programs for cytisinicline, specifically aimed at addressing the unmet need for smoking cessation and e-cigarette cessation therapies. Management continues to prioritize the regulatory strategy required to bring its lead candidate to market, maintaining significant expenditures on research and development while managing capital resources to support ongoing clinical trial requirements. Liquidity management remains the core financial theme, with cash and cash equivalents of approximately $28.08 million as of the end of the first quarter. The company continues to operate with a lean organizational structure while executing its clinical milestones, reflecting its commitment to extending cash runway as it navigates the regulatory and clinical approval processes.

Key Takeaways for Achieve Life Sciences Inc

• Achieve Life Sciences continues to focus on its clinical development program for cytisinicline, targeting regulatory submission for smoking cessation and potentially vaping cessation.
• The company reported a net loss of $10.17 million for Q1 2026, driven primarily by ongoing R&D expenditures to support clinical trial operations.
• Cash and cash equivalents stood at $28.08 million as of March 31, 2026, requiring careful capital management to sustain operations ahead of potential commercialization.
• The company has no commercial revenue, and financial results are dominated by R&D spending and administrative costs typical of a clinical-stage biotechnology entity.
• Regulatory pathway milestones for cytisinicline remain the most critical catalyst for the business, as successful trial data is essential for long-term survival and potential market entry.

What Does Achieve Life Sciences Inc Do?

Achieve Life Sciences Inc. is a pharmaceutical company dedicated to the development of cytisinicline, a plant-based alkaloid aimed at treating nicotine addiction. The company's primary target is the massive global market for smoking cessation, with a secondary focus on potential treatments for nicotine e-cigarette (vaping) cessation. The company operates as a clinical-stage entity, meaning it does not currently sell any products and does not generate commercial revenue. Its business model relies on conducting clinical trials—specifically the ORCA program—to secure FDA approval for its treatment. Upon approval, the company intends to commercialize cytisinicline as a first-line treatment for nicotine dependency, addressing a significant public health need.